

**3rd International Workshop on Vaccine Adjuvants and Glycoconjugates**  
**From 16th to 20th of april 2006 in Club Amigo Hotel, Varadero, Cuba**

**PROGRAM**

<b>Day</b>	<b>Time</b>	<b>Activity</b>
<b>16</b>	8:00	Depart from Havana
	9.00	Contact with Nature (Foreign delegates)
	14:30	Arrival and Registration
	17:30	Welcome Ceremony
	18:00	Opening Conference: Cuban strategies on Adjuvants. <b>O Pérez</b> , Cuba
	19:30	Dinner
<b>17</b>	<b>Mechanism of action of adjuvants</b>	
	Chairman: Virgil Schijns and M.E. Lanio	
	08:30-09:30	<b>Keynote address: The important role of immunopotentiators in modern vaccines.</b> V Schijns, The Netherlands
	09:30-10:00	<b>MedDC: a fully functional human DC-like artificial antigen presenting cells.</b> K Yokokawa, Japan
	10:00-10:30	<b>Sticholysin II (St II), a pore forming protein isolated from the sea anemone Stichodactyla helianthus with immunomodulator properties.</b> ME Lanio, Cuba
	10:30-11:00	<b>Coffee Brake</b>
	11:00-11:30	<b>Early protection against foot and mouth disease elicited in bovines, using inactivated vaccines and aqueous adjuvants.</b> P Zamorano, Argentina
	11:30-12:00	<b>MONTANIDE ISA 51 VG as Adjuvant for Human Vaccines</b> J GAUCHERON, France
	<b>Glycoconjugate vaccines</b>	
	Chairman: LA Mulard and O Cabrera	
	12:00-12:30	<b>Synthetic carbohydrate-protein conjugates as potential vaccines against Shigella flexneri serotype 2a.</b> LA Mulard, France
	12:30-12:45	<b>Design and characterization of protein-dimeric polysaccharide conjugate against <i>Neisseria meningitidis</i> serogroups A and C.</b> O Cabrera, Cuba
	12:45-14:00	<b>LUNCH</b>
	<b>Procedures for testing new adjuvants</b>	
	Chairman: PM Dubois and S Sifontes	
	14:00-14:30	<b>Current Perspectives on the Preclinical Testing of Preventive Vaccines &amp; Adjuvants.</b> S Sifontes, Cuba
	14:30-15:00	<b>Analyzing toxicological aspects of immunological adjuvants for vaccine and experimental use.</b> A Batista, Cuba
15:00-15:30	<b>Monitoring T cell responses: From animal models to the clinic.</b> PM Dubois, Belgium	
15:30-	<b>Poster Discussion and Rum tasting</b>	

<b>18</b>	<b>Adjuvant for Mucosal Vaccines</b>	
	Chairman: A Harandi, and E. Lavelle	
	08:30-09:30	<b>Keynote address: Mechanism of action of mucosal vaccine adjuvants.</b> E Lavelle, Ireland
	09:30-10:00	<b>Novel CpG oligodeoxynucleotide-based strategies for induction of mucosal immunity in the female genital tract.</b> A Harandi, Sweden
	10:00-10:30	<b>Dendritic cell-mediated induction of mucosal cytotoxic responses following MUCOSAL immunization with Cholera toxin derivatives.</b> F Anjuère, France
	10:30-11:00	<b>Coffee Brake</b>
	11:00-11:30	<b>NASVAC, a nasal vaccine candidate for chronic Hepatitis B immunotherapy.</b> V Muzio, Cuba
	<b>Contact with Nature</b>	
	12:00-12:30	<b>Plant-derived pharmaceuticals: Current developments and perspectives.</b> M Pujol, Cuba
12:30-13:00	<b>Possibilities to increase your contact with wildlife in Cuba.</b> G Hernández, Cuba	

13:00-14:00

LUNCH

<b>18</b>	<b>Adjuvant for Therapeutic Vaccines</b>	
	Chairman: F Mahboudi and LE Fernandez	
	14:00-14:30	<b>Phenotypic and functional characterization of aminobisphosphonate-activated gdT LAK cells- Application for gdT cell-based immunotherapy.</b> M Nieda, Japan
	14:30-15:00	<b>Combining potent immune suppressants with strong pro-inflammatory ligands in VSSP: A new road for cancer vaccines adjuvants.</b> LE Fernandez, Cuba
	15:00-15:30	<b>Vibrio cholera bacterial ghost as delivery system induces immunological responses against Leishmania major glycoprotein gp63 DNA IN Balb/c mice.</b> F Mahboudi, Iran
	15:30-16:00	<b>Immunological evaluation of a new vaccine candidate based on the adjuvant effect of the recombinant HBV surface and core antigens on CR3, an HIV-based multi-epitopic protein.</b> E Iglesias, Cuba
	16:00-16:15	<b>Induction of Full Anti-tumour Protection by Post-operative Immunization With GM3/VSSP Vaccine in a Pre-Clinical Mouse Melanoma Model.</b> Z Mazorra, Cuba

17:00-

**Sport Competitions between Foreign and National delegates**

22:00-23:00

**Cuban Film**

<b>19</b>	<b>Proteo-Cochleate as adjuvants</b>	
	Chairman: M Friede and RL Solís	

	08:30-09:30	<b>Keynote address: Development of and access to adjuvants: the need for novel adjuvants in the public sector.</b> M Friede, WHO
	09:30-10:00	<b>Influence of outer membrane vesicles in MenB vaccines.</b> R Barberá, Cuba
	10:00-10:30	<b>Influence of Proteoliposome onto Alum.</b> D González, Cuba
	10:30-11:00	<b>Coffee Brake</b>
	11:00-11:30	<b>Proteoliposome and Cochleate adjuvants.</b> O Pérez, Cuba
	11:30-12:00	<b>Intranasal immunization with proteoliposome-derived cochleate containing recombinant gD2 protein confers protective immunity against genital herpes infection in mice.</b> J del Campo, Cuba-Sweden
	12:00-12:30	<b>Meningococcal outer membrane cochleate structures as adjuvant for Malaria antigens.</b> G Bracho, Cuba-Australia

12:30-14:00	<b>LUNCH</b>
-------------	--------------

<b>19</b>	14:00-14:30	<b>New Cochleate from <i>Vibrio cholerae</i> Proteoliposome.</b> R Acevedo, Cuba
	14:30-15:00	<b>The anti-allergic protecting effect of bacterial-derived proteoliposome as allergen adjuvant in the context of changing paradigms in allergy immunotherapy.</b> A Labrada, Cuba

21:00-	<b>Dancing activity</b>
--------	-------------------------

<b>20</b>	08:30-12:00	<b>Bilateral meetings</b>
	12:00-13:00	<b>LUNCH</b>
	14:00	<b>Transfer to Havana</b>

### Posters Program

Session	Title and Authors
<b>A-1</b>	<b>Modulation of the immune response induced by a genetic vaccine against bovine herpes virus (BHV-1) using different adjuvants.</b> Langellotti C, Pappalardo S, Mongini C, Quattrocchi V, Cebrian I, Taboga O and Zamorano P. Argentina.
<b>A-2</b>	<b>Immunomodulatory effect of a <i>M. tuberculosis</i> expression library on the protective response</b>

	<b>of BCG immunized mice against a mycobacterial challenge.</b> López Y, Yero D, Sifontes S, Infante JF, Pérez M, Sarmiento ME, Díaz D, Parajón E and Acosta A. Cuba.
<b>A-3</b>	<b>Preclinical evaluation in mice of the immunogenicity of a novel adjuvanted anti-allergic vaccine.</b> Ramírez W, Labrada A, Facenda E, Bourg V, González B, Lastre M and Pérez O. Cuba.
<b>A-4</b>	<b>Isolation of Bacillus cereus and potentiality like immunomodulator.</b> Pérez I, Orberá T, Tamayo JL. Cuba.
<b>A-5</b>	<b>Study of the adjuvant effect of cliptox on the immune response induced by an inactivated vaccine against foot and mouth disease virus and a DNA vaccine against bovine herpes virus-1.</b> Batista A, Olivera V, Langellotti C, Quattrocchi V, Pappalardo S, Mongini C and Zamorano P. Cuba –Argentina
<b>A-6</b>	<b>Immunomodulatory properties of natural product obtain from stem bark of Mangifera indica l (vimang) and its glucosilxantona, mangiferin.</b> Delgado R, Garrido G, García D, Pardo GL, Martínez G, Hernández P, Rodeiro I, Hernandez I, Sanchez C, Guevara M, Alvarez A, Rodríguez PC, Morffi J , Merino N, Gonzalez RM, Núñez AJ, Cuba.
<b>A-7</b>	<b>Effective tumor immunotherapy that uses an HPV 16/ E7 CTL epitope and VSSP in mice.</b> Torréns I, Mendoza O, Reyes O, Batte A, Fernández LE, Guillén G & Granadillo M. Cuba
<b>B-1</b>	<b>Vaccine against bovine herpesvirus 1 using the tetanic toxin as an adjuvant and an attenuated Salmonella strain to deliver it.</b> Cebrián JI, Pappalardo S, Langelotti C, Quattrocchi V, Taboga O, Batista A, Chabalgoity A, Sadir A and Zamorano P, Argentina
<b>B-2</b>	<b>The antibody response to recombinant protein NMB1126 from Neisseria meningitidis with different adjuvants.</b> Niebla O, Yero D, Cobas K, and Pajón R. Cuba
<b>B-3</b>	<b>A new attractive method for refolding and increasing the immunogenicity of recombinant antigens.</b> Niebla O, Delgado M, Yero D, de la Caridad Y, and Pajón R. Cuba
<b>B-4</b>	<b>Comparison of divergent delivery methods for an HIV DNA vaccine in preclinical model.</b> Malm M, Pirinen M, Karlsberg M, Myllymäki T, Männik A, Ustav M, Blazevic V. Finland
<b>B-5</b>	<b>New trends in adjuvants: use of Proteoliposome as adjuvant in potential candidate vaccines.</b> Hernández J and Pérez O. Cuba
<b>B-6</b>	<b>Hepatitis C virus Core protein as a potential molecular adjuvant to DNA vaccines.</b> Acosta-Rivero N, Musacchio A, Poutu J, Manrique V, Aguilera Y, Alvarez-Lajonchere L, Alvarez-Obregón JC, Guerra I, Viña A, Pérez A, Aguilar JC, Morales J, Falcón V, Marante J, Dueñas S. Cuba
<b>C-1</b>	<b>Mucosal and systemic immune responses to meningococcal c polysaccharide-tetanus toxoid conjugate in mice.</b> Cuello M, Cabrera O, del Campo JM, Camaraza MA, Sotolongo F, Pérez O, Sierra G. Cuba
<b>D-1</b>	<b>Outer membrane vesicles of Neisseria lactamica as a potencial mucosal adjuvant.</b> Sardiñas G, Reddin K, Pajon R, and Gorringe A. Cuba
<b>D-2</b>	<b>Intraperitoneal administration of freund´s adjuvant IN neonatal mice negatively influences the levels of bacteremia achieved after challenge with meningococci.</b> González S, Pérez YC, Blanco A, Cobas K. and Pajón R. Cuba
<b>D-3</b>	<b>Cholera vaccine candidate proteoliposome as a potential adjuvant.</b> Pérez JL, González Y, Año G, Cedré B, Valmaseda T, Acevedo R, González L, Cabrera RA, Talavera A, Martínez I, Pérez O and García L. Cuba
<b>D-4</b>	<b>Immunogenic properties of a Proteoliposome From Vibrio cholerae O1, El Tor Ogawa.</b> González Y, Pérez JL, Año G, Cedré B, Valmaseda T, Cabrera RA, Martínez I, Milián E, Fariñas M, Serrano D, Talavera A and García L. Cuba
<b>D-5</b>	<b>Use of cholera toxin as adjuvant for the production of secretory IgA monoclonal antibodies against M. tuberculosis antigens.</b> Falero G, Acosta A, Challacombe S, López Y, Pérez ME, Rodríguez I, Rahman D, Sarmientos ME, Mistry M, Otero O, Douce G, Puig A, Dougan G,

	Olivares N, William A, Infante JF, Reljic R, Sierra G, Marsh P, Solís RL, Ivanyi J. Cuba
E-1	<b>Obtention and preliminar immunological evaluation of two proteic antigens for the antiangiogenic immunotherapy of cancer.</b> Morera Díaz Y, Bequet M, Ayala M, Gavilondo JV. Cuba.
E-2	<b>Evaluation of the recombinant fusion protein expressed in Escherichia coli that includes domain III of the Dengue Type 1 viral envelope protein in nonhuman primates adjuvated in freund and aluminum hydroxide.</b> Bernardo L, Izquierdo A, Alvarez M, Rosario D, Prado I, López C, Sierra B, Martínez R, Castro J, Santana E, Hermida L, Guillen G and Guzmán MG. Cuba
E-3	<b>Western blot profile in sera from nonhuman primates immunized with domain III of the Dengue type 1 and 2 envelope proteins adjuvated in freund and aluminum hydroxide.</b> Cabezas S, Bernardo L, Izquierdo A, Alvarez M, Rosario D, López C, Martínez R, Castro J, Hermida L, Guillen G and Guzmán MG. Cuba
E-4	<b>Influence of the aluminum-based adjuvant and formulation over the immune-response to a multi-epitopic protein from HIV-1 co-administered with surface and core antigens of HBV.</b> Iglesias E, Franch O, Carrazana Y, Lobaina Y, García D, Sánchez J, Sánchez J, Urquiza D, Cruz O, Muzio VL, Guillén G, Aguilar JC. Cuba
E-5	<b>Comparative immunogenicity and safety of four alum adjuvated-recombinant hepatitis b vaccines in healthy adults.</b> Hernández F, Aguilar A, Pérez K, Aljovin V, Hernández K, Figueredo N, Arias G, Oquendo O, Aleman R, García E, Figueroa N, Delahanty A, Trujillo J, Juvier AI, Véliz G, Cinza Z y Muzio VL. Cuba.
E-6	<b>Increasing the immunogenicity of meningococcal outer membrane vesicles by using different DNA molecules.</b> Yero D, Acosta M, Niebla O, Caballero E, Cobas K, Fariñas M, Diaz D, Sifontes S, Pérez Y, Almagro M, Delgado M, Acosta A y Pajón R. Cuba
F-1	<b>Preclinical toxicity testing plan of cochleate in sprague dawley rats.</b> Infante JF, Sifontes S, Lastre M, del Campo J, Bracho G, Sosa E, Pérez V, Díaz D, Hernández T, Torres V, Rodríguez N, Fariñas M, Zayas C, and Pérez O. Cuba
G-1	<b>Evaluation of the recombinant proteins P64k-dengue formulated in two different adjuvants.</b> Valdés I, Hermida L, Martín J, Lazo L, Zulueta A, López C, Bernardo L, Silva R, China G, del Rosario D, Guzmán MG. and Guillén G. Cuba
G-2	<b>Prophylactic naked DNA vaccination with the human vascular endothelial growth factor isoform 121 induces anti-tumor response in C57BL/6 mice.</b> Bequet M, Ayala M, Acevedo BE, Galbán E, López O, Torrens I, Gavilondo JV. Cuba